VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

“New technologies such as gene and cell therapies hold out ... oedema seen in trials of other CAR-T candidates from Kite Pharma and Juno. The FDA has approved a Risk Evaluation and Mitigation ...

London, UK-based Autolus said the CAR-T is the first to be approved ... Two rival CAR-Ts are currently approved by the FDA for relapsed or refractory B-cell precursor ALL, namely Novartis' Kymriah ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

DUBLIN--(BUSINESS WIRE)--The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This report provides ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

SynKIR-310 is a chimeric antigen receptor (CAR) T-cell therapy that relies on DS191. Like commercially approved CAR T-cell therapies, SynKIR-310 is directed by DS191 to target a similar epitope of ...

Larger studies are needed to assess efficacy, but early data suggest this approach could offer a less toxic alternative to CAR-T cell therapies that are approved by the Food and Drug ...

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. It highlights approved CAR-T therapies and late-stage clinical trials that ...